R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy

Summary:HIV-1 coreceptor usage plays a critical role for virus tropism and pathogenesis. A switch from CCR5 to CXCR4-using viruses can occur in the natural course of infection and correlates with subsequent disease progression. To investigate whether HIV-1 genetic evolution might lead to changes in virus coreceptor usage during highly active antiretroviral therapy (HAART), a longitudinal genotypic analysis of the virus found in cellular reservoirs was conducted in 32 patients with undetectable viral loads on HAART for 5 years. The genotype of the 3rd variable region of the env gene predicting coreceptor usage was retrospectively determined in the plasma or in peripheral blood mononuclear cells (PBMC) at baseline and then in PBMCs at months 30 and 60 of HAART. There was a switch from R5 to X4 variants in 11 of the 23 patients who harbored a majority virus population of R5 variants at baseline. X4 variants remained predominant in the 9 patients who harbored mainly X4 variants at baseline. The patients harboring predominantly X4 variants during HAART, either from baseline or after an R5 to X4 switch, tended to have lower CD4+ T-cell counts on HAART than did patients harboring continuously a majority population of R5 variants. These results suggest that potent antiretroviral therapy produces the conditions necessary for the gradual emergence of X4 variants in cellular reservoirs.

[1]  Robert F. Siliciano,et al.  Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[2]  K. Anastos,et al.  Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. , 2001, The Journal of clinical investigation.

[3]  R. Paranjape,et al.  Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. , 2000, Virology.

[4]  J. Sleasman,et al.  Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). , 2000, AIDS.

[5]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[6]  Mario Roederer,et al.  T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.

[7]  Anthony S. Fauci,et al.  Both Memory and CD45RA+/CD62L+ Naive CD4+ T Cells Are Infected in Human Immunodeficiency Virus Type 1-Infected Individuals , 1999, Journal of Virology.

[8]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[9]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[10]  David Camerini,et al.  Expression and Function of Chemokine Receptors on Human Thymocytes: Implications for Infection by Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[11]  A. Lafeuillade,et al.  Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. , 1998, The Journal of infectious diseases.

[12]  P. Vernazza,et al.  Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.

[13]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[14]  R. Corrêa,et al.  Viral phenotype affects the thymic production of new T cells in HIV-1-infected children , 2001, AIDS.

[15]  P. Massip,et al.  Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. , 2002, Virology.

[16]  H. Schuitemaker,et al.  Both R5 and X4 Human Immunodeficiency Virus Type 1 Variants Persist during Prolonged Therapy with Five Antiretroviral Drugs , 2002, Journal of Virology.

[17]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[18]  Jaap Goudsmit,et al.  N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* , 2001, The Journal of Biological Chemistry.

[19]  J. McNamara,et al.  A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. , 1998, The Journal of pediatrics.

[20]  James I Mullins,et al.  Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy , 2004, AIDS.

[21]  J. Metcalf,et al.  HIV-1 replication in patients with undetectable plasma virus receiving HAART , 1999, The Lancet.

[22]  G. d’Ettorre,et al.  Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy , 2003, Journal of medical virology.

[23]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[24]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[25]  F. Barré-Sinoussi,et al.  Positive Regulation of CXCR4 Expression and Signaling by Interleukin-7 in CD4+ Mature Thymocytes Correlates with Their Capacity To Favor Human Immunodeficiency X4 Virus Replication , 2003, Journal of Virology.

[26]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[27]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[28]  M. Sim,et al.  Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. , 2000, The Journal of infectious diseases.

[29]  B. Haynes,et al.  Immune reconstitution in patients with HIV infection. , 2002, Annual review of medicine.

[30]  M. Rey-Cuillé,et al.  N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. , 2001, AIDS research and human retroviruses.

[31]  J. Margolick,et al.  Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[32]  C. Mackay,et al.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Rami Kantor,et al.  High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment , 2003, Journal of Virology.

[34]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[35]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[36]  B. Clotet,et al.  Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. , 1999, Virology.

[37]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[38]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[39]  E. Nicastri,et al.  HIV phenotype switching during antiretroviral therapy: emergence of saquinavir‐resistant strains with less cytopathogenicity , 1997, AIDS.

[40]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[41]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[42]  R. Lal,et al.  CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. , 1998, Virology.

[43]  J. Barretina,et al.  Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals , 2001, Journal of Virology.

[44]  C. Farber,et al.  In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. , 1995, AIDS.

[45]  Alan S. Perelson,et al.  Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.

[46]  V. Trouplin,et al.  Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations , 2003, AIDS.

[47]  H. Schuitemaker,et al.  In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[49]  L. Ratner,et al.  Analysis of the Critical Domain in the V3 Loop of Human Immunodeficiency Virus Type 1 gp120 Involved in CCR5 Utilization , 1999, Journal of Virology.

[50]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.